{"drugs":["Finafloxacin","Xtoro"],"mono":{"0":{"id":"931319-s-0","title":"Generic Names","mono":"Finafloxacin"},"1":{"id":"931319-s-1","title":"Dosing and Indications","sub":{"0":{"id":"931319-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Otitis externa, acute, Caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus:<\/b> 4 drops into affected ear(s) twice daily for 7 days<\/li><li><b>Otitis externa, acute, Caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus:<\/b> With otowick: 8 drops into affected ear(s) for first dose, followed by 4 drops twice daily for 7 days<\/li><\/ul>"},"1":{"id":"931319-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Otitis externa, acute, Caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus:<\/b> (1 year or older): 4 drops into affected ear(s) twice daily for 7 days<\/li><li><b>Otitis externa, acute, Caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus:<\/b> (1 year or older) with otowick: 8 drops into affected ear(s) for first dose, followed by 4 drops twice daily for 7 days<\/li><\/ul>"},"3":{"id":"931319-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Otitis externa, acute, Caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus<br\/>"}}},"3":{"id":"931319-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931319-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"931319-s-3-10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- Allergic reaction may occur, especially in patients with a history of hypersensitivity to finafloxacin, other quinolones, or any component of the product; discontinue use if suspected and initiate alternative therapy<\/li><li>-- Overgrowth of nonsusceptible organisms (eg, yeast and fungi) may occur with prolonged use; discontinue use if suspected and initiate alternative therapy<\/li><\/ul>"},{"id":"931319-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"931319-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"931319-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (1%)<\/li><li><b>Otic:<\/b>Pruritus, Of the ear (1%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Allergic reaction, Infection due to resistant organism<br\/>"},"6":{"id":"931319-s-6","title":"Drug Name Info","sub":{"0":{"id":"931319-s-6-17","title":"US Trade Names","mono":"Xtoro<br\/>"},"2":{"id":"931319-s-6-19","title":"Class","mono":"Fluoroquinolone<br\/>"},"3":{"id":"931319-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"931319-s-7","title":"Mechanism Of Action","mono":"Finafloxacin, a fluoroquinolone antibiotic, inhibits bacterial type 2 topoisomerase enzymes, DNA gyrase, and topoisomerase IV, which are necessary for bacterial DNA replication, transcription, repair, and recombination.<br\/>"},"9":{"id":"931319-s-9","title":"Administration","mono":"<b>Otic<\/b><br\/><ul><li>Warm bottle by hand for 1 to 2 minutes prior to administration<\/li><li>Shake well before use<\/li><\/ul>"},"10":{"id":"931319-s-10","title":"Monitoring","mono":"Reduction in the symptoms of acute otitis externa may indicate efficacy.<br\/>"},"13":{"id":"931319-s-13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include pruritus of the ear or nausea.<\/li><li>Advise patient to immediately report allergic reaction.<\/li><li>Instruct patient to warm solution in their hands for at least 1 to 2 minutes before administration to ear.<\/li><li>Counsel patient on appropriate dosing  and instillation techniques.<\/li><\/ul>"}}}